Objective To investigate the association between prostate stem cell antigen (PSCA) gene single nucleotide acid polymorphism (SNP) and prostate cancer (PCa) in patients undergone prostate biopsy.Methods DNA from 296 patients undergoing prostate biopsy was typed for PSCA rs1045531 SNP.The frequency of rs1045531 polymorphism between PCa patients and benign prostatic hyperplasia (BPH) patients were compared.The associations between its polymorphism with the risk of PCa and prostate specific antigen (PSA) were analyzed.Results Frequency of PSCA rs1045531 genotypes were significant difference between PCa and BPH patients (P =0.000).Patients with AC genotype had a significantly higher risk for developing PCa compared to patients with CC genotype [odds ratio (OR) =2.612,95％ confidence interval (CI):1.607-4.245,P =0.000].The PSA in patients with AC genotype was significantly higher than that in patients with CC.There is association between rs1045531 SNP with Gleason score (x2 =10.370,P =0.006).Conclusion PSCA rs1045531 SNP can be used in evaluating the risk and prognosis of PCa in patients undergoing prostate biopsy.

Background and Purpose:This study explored the association between a single-nucleotide polymorphism of prostate stem cell antigen and prostate cancer in Chinese patients undergoing prostate biopsy. Materials and Methods:DNA from 416 patients undergoing prostate biopsy was typed for the prostate stem cell antigen rs1045531 single-nucleotide polymorphism. The frequency of the rs1045531 polymorphism in patients with prostate cancer and in patients with benign prostatic hyperplasia was compared. Associations between the polymorphism and the risk of prostate cancer, prostate special antigen, Gleason score, and clinical stage were analyzed. Results:Statistically significant differences in the distribution of the rs1045531 genotypes and alleles were found between prostate cancer and benign prostatic hyperplasia in patients undergoing prostate biopsy (P = .035 and .046, respectively). We found that the rs1045531 AC genotype was significantly associated with a high risk of prostate cancer in the heterozygote model (AC vs CC; odds ratio = 2.383, 95% confidence interval: 1.198-4.741, χ2 = 6.229, P = .013) and the dominant model (AA/AC vs CC; odds ratio = 2.169, 95% confidence interval: 1.112-4.229, χ2 = 5.228, P = .022). However, susceptibility of prostate cancer was decreased in the homozygote model (AA vs CC; odds ratio = 0.828, 95% confidence interval: 0.143-4.805, P = .601). When considering clinical factors, the rs1045531 showed an association with prostate special antigen of 10 ng/mL or greater, a Gleason score of 7 or greater, and a size of T2 or greater. Conclusion:Men with the rs1045531 AC genotype of prostate stem cell antigen were at higher risk of prostate cancer in Chinese patients undergoing prostate biopsy.

Objective To investigate the difference of red blood cell distribution width (RDW) between the patients with prostate cancer (PCa) and benign prostatic hyperplasia (BPH ) .Methods RDW values of 877 consecutive patients underwent prostate biopsy were retrospectively analyzed .The difference of RDW values was compared between PCa cases (group PCa ,385 cases) and BPH cases (group BPH ,492 cases) .The optimal cutoff value of RDW for the diagnosis of PCa was determined with the ROC curve .The positive rate of prostate biopsy was compared between two groups .Results RDW was higher in group PCa than that in group BPH [(13.34 ± 1.24)% vs .(12.78 ± 0.64)% ] (P<0 .01) .Taking 13.05% as the cutoff value in predicting the positive prostate biopsy ,the positive prostate biopsy rate was 59.3% in the cases with RDW >13.05% and 32.6% in those with RDW ≤13.05% (P<0 .01) .Conclusion RDW may be a predicting factor for PCa .The positive rate of prostate biopsy increases in the patients with RDW greater than 13.05% .

Objective To assess the clinical significance of red blood cell distribution width ( RDW) in patients undergone prostate biopsy.Methods A total of 793 consecutive patients were enrolled, with 359 cases of prostate cancer ( PCa) and 434 cases of benign prostate hyperplasia ( BPH) diagnosed by pathological examination.The difference of RDW level between PCa and BPH patients was analyzed by T-test.Logistic regression was used to evaluate the contributed factors such as RDW, PSA, HB, WBC, PLT, TG and age.Areas under operating characteristic curves ( AUC) were used to compare the predictive power of RDW for the presence of PCa among different PSA level groups.The difference of RDW level was also analyzed in different groups divided by PSA, Gleason score and clinical stage respectively.Simple linear regression analysis was performed to explore the association of RDW with PSA, Gleason score and clinical stage.Results The means of RDW were ( 13.38 ±1.11 )%in patients with PCa which were higher than those with BPH (12.75 ±0.62)%(P<0.001).The odds ratio of RDW was larger than that of PSA and age according to the Logistic regression analysis.AUC of RDW was 0.730 in the patients with PSA>20 ng/ml, the highest in the PSA groups.The RDW was positively correlated with increasing risk evaluated by PSA, Gleason score or clinical stage (P<0.05) .Conclusions RDW of PCa patients is higher than BPH, and it is the independent factor correlating with prostate biopsy results, which can be used to predict positive prostate biopsy, especially in patients with PSA>20 ng/ml.Therefore, RDW can be used to evaluate the risk of prostate cancer.

Objective To validate and compare the predictive accuracy of four prostate cancer models designed to predict the likelihood of a positive initial transrectal biopsy.Methods Clinical data of 813 consecutive patients between January 2010 and September 2014 who had undergone a transrectal ultrasound (TRUS) guided prostate biopsy at our institution were reviewed,431 patients fulfilling all criteria for four predictive models were enrolled for the final analysis.The risk of each individual positive biopsy was calculated using either of the four models.The predictive accuracy of each model was measured using area under the receiver operating characteristic curve (AUC),and the comparison of AUCs was performed by Z test.Results Of 431 participants,the statistical analysis of age,prostate-specific antigen (PSA),digital rectal examination (DRE),prostate volume and TRUS findings were all significantly different (P ＜ 0.05),except percentage of free prostate-specific antigen (％ fPSA) (P =0.242).AUCs were 0.774 (95％ CI 0.726-0.822),0.765 (95％ CI0.714-0.816),0.813 (95％ CI0.767-0.858),0.795 (95％ CI0.749-0.842) and 0.736 (95％ CI 0.684-0.788) for the North-American prostate cancer prevention trial derived cancer risk calculator (PCPT-CRC) model,Montreal model,domestic model 1,domestic model 2 and PSA alone,respectively.There was no significant difference among AUCs of the four models,and a 7.7％ increased predictive accuracy was observed for the domestic model 1 compared to unlimited PSA alone(P ＜0.05).When serum PSA ranging from 4 to 10 ng/ml,AUCs were 0.688 (95％ CI 0.560-0.816),0.818 (95％ CI0.719-0.918),0.830 (95％ CI0.740-0.919),0.853(95％ CI0.771-0.935) and 0.565(95％ CI 0.419-0.710) for the four models and PSA alone,respectively.Domestic model 2 owned the highest predictive accuracy and a 28.8％ increased predictive accuracy was observed for the domestic model 2 compared to PSA alone (P ＜ 0.05).Conclusions External validation and comparison of the four models reveals that all of the four models have acceptable predictive accuracy in our cohort.There is no difference of predictive accuracy between foreign and domestic models according to the AUC results.However,domestic model 1 is superior to unlimited PSA alone,and domestic model 2 has the highest predictive accuracy when serum PSA ranging from 4 to 10 ng/ml.

Objective To assess the correlation between high sensitive C-reactive protein and bone metastasis of patients with newly diagnosed prostate cancer.Methods From Jan.2010 to Dec.2015,a total of 294 consecutive patients with newly diagnosed prostate cancer by prostate biopsy were enrolled in this study.The median age was 70(65-75) years.There were 90(30.6％) patients with a positive DRE (digital rectal examination).The median prostate volume,PSA and PSAD were 36.5 ml(25.2-53.1 ml),32.95 ng/ml(14.49-82.89 ng/ml) and 0.90 ng/(ml · cm3) [0.44-1.95 ng/(ml · cm3)],respectively.There were 37 (12.6％) patients with a Gleason score ≤ 6,97 (33.0％) with a Gleason score of 7 and 160 (54.4％) with a Gleason score ≥ 8.Clinical stage was also evaluated,including 94(32.0％) diagnosed as T1 stage,132(44.9％) T2 stage,50(17.0％) T3 stage,and 18(6.1％) T4 stage.Regional lymph node metastases were found in 29 (9.9％) patients.All patients underwent bone scan and 59 patients showed bone metastases.One patient showed pulmonary metastases by computed tomography (CT).The difference of hs-CRP level between patients with bone metastasis and without bone metastasis was analyzed by MannWhitney U test.The difference of bone metastasis rate between the patients with elevated hs-CRP level (hsCRP ＞3.0 mg/L) and normal hs-CRP (hs-CRP≤3.0 mg/L) level was analyzed by Chi-squared test.Logistic regression was used to evaluate the effect of hs-CRP,prostate specific antigen (PSA),prostate specific antigen density (PSAD),Gleason score and clinical stage on bone metastasis.Areas under operating characteristic curves (AUC) were used to compare the predictive value of hs-CRP,PSA and PSAD.Restlts The hs-CRP level of the 294 patients ranged from 0.77 mg/L to 6.33 mg/L,with a median of 1.80 mg/L.The median (interquartile range) of hs-CRP was 6.90 mg/L (1.95-13.74 mg/L) in patients with bone metastasis which is higher than 1.43 mg/L (0.70-4.32 mg/L) in those without bone metastasis (P ＜ 0.05).The level of PSA,Gleason score and clinical stage were also significantly different between the two groups (P ＜ 0.05).The rate of bone metastasis in patients with elevated hs-CRP was 37.2％ (42/113),higher than that of patients with normal hs-CRP(P ＜ 0.001).According to the logistic regression analysis,hs-CRP (OR =1.149,95％ CI 1.080-1.222,P ＜ 0.05),PSA (OR =1.013,95％ CI 1.002-1.023,P ＜ 0.05) and Gleason score(OR =2.515,95％ CI 1.198-5.279,P ＜ 0.05) were significant independent predictors for bone metastasis.AUC of hs-CRP was 0.720 and the cutoff value was 3.1 mg/L.Conclusions High hs-CRP is significantly correlated with bone metastasis.Measurement of hs-CRP plays an important role in predicting bone metastasis among patients with newly diagnosed prostate cancer.